L.p.

Sodium Valproate, the active ingredient in L.p., is an anticonvulsant presented as an oral formulation for oral use. It is employed in the management of various seizure types, bipolar disorder manic episodes, and migraine prevention in adult patients. GNH USA supplies L.p. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sodium Valproate is used to treat disorders involving abnormal neuronal excitability. - Epilepsy: reduces the frequency of generalized and focal seizures. - Bipolar disorder: stabilizes mood during manic episodes. - Migraine prophylaxis: decreases the occurrence of migraine attacks.

Sodium Valproate may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Tremor: fine shaking of hands or limbs. - Weight gain: gradual increase in body weight. - Hair loss: diffuse thinning of scalp hair. - Drowsiness: increased sleepiness or fatigue. - Elevated liver enzymes: mild hepatic enzyme rise.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury, especially in children. - Pancreatitis: inflammation of the pancreas with abdominal pain. - Thrombocytopenia: low platelet count leading to bleeding risk. - Hyperammonemia: elevated blood ammonia causing confusion. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Birth defects: high teratogenic risk if exposure occurs during pregnancy.

When prescribing Sodium Valproate, clinicians should consider several safety measures. - Liver monitoring: assess hepatic function before and during therapy. - Blood counts: regularly check platelet and white‑cell counts. - Pregnancy risk: avoid use in women of childbearing potential unless no alternatives exist. - Drug interactions: review concomitant medications for potential interactions. - Renal function: adjust use in patients with impaired renal clearance. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Sodium Valproate interacts with several drug classes, requiring careful management.

Major Interactions (Avoid): - Carbamazepine: may reduce valproate levels and increase toxicity. - Phenobarbital: can lower valproate concentrations, diminishing efficacy. - Warfarin: valproate may potentiate anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely): - Lamotrigine: risk of severe skin reactions; dose adjustments needed. - Topiramate: may increase valproate serum levels. - Oral contraceptives: valproate can reduce hormonal efficacy, risking unintended pregnancy.